Asset Details
Do you wish to reserve the book?
Clinical outcomes of a 12-week, first treatment with methylphenidate in an Italian representative sample of children and adolescents with ADHD
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical outcomes of a 12-week, first treatment with methylphenidate in an Italian representative sample of children and adolescents with ADHD
Do you wish to request the book?
Clinical outcomes of a 12-week, first treatment with methylphenidate in an Italian representative sample of children and adolescents with ADHD
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical outcomes of a 12-week, first treatment with methylphenidate in an Italian representative sample of children and adolescents with ADHD
2025
Overview
Current clinical guidelines suggest methylphenidate (MPH) as first-line option for treatment of attention-deficit/hyperactivity disorder (ADHD). However, the Lombardy ADHD Registry initiative has recently raised some concerns about discrepant therapeutic approaches between different clinical centers. In this naturalistic observational study, we report the experience of a third-level referral center in monitoring care services for young ADHD patients. We described the clinical characteristics of the children/adolescents who were diagnosed with ADHD from 2017 and prescribed or not with MPH. We further followed-up ADHD patients who were taking MPH for 12 weeks to assess any clinical amelioration using the Clinical Global Impression—Severity scale, controlling for other outcome predictors. One fourth of patients received a MPH prescription after the ADHD diagnosis. Those children/adolescents showed more complex clinical manifestations, with greater ADHD difficulties and neuropsychiatric comorbidities. ADHD patients displayed significant improvements of functioning after 12 weeks of the initiation of MPH use, but not after 4 weeks. IQ level and the presence of co-occurring autism predicted ADHD severity at baseline. After controlling for other predictors’ effect, the severity at the first visit predicted ADHD severity after 4 weeks of MPH use, which in turn predicted the clinical functioning at the 12-week visit.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/308
/ 692/700
/ Attention Deficit Disorder with Hyperactivity - drug therapy
/ Attention Deficit Disorder with Hyperactivity - epidemiology
/ Attention deficit hyperactivity disorder
/ Autism
/ Central Nervous System Stimulants - therapeutic use
/ Child
/ Children
/ Female
/ Gender
/ Humanities and Social Sciences
/ Humans
/ Insomnia
/ Male
/ Methylphenidate - therapeutic use
/ Patients
/ Science
